Speedy US approval for Novartis' Tabrecta

6th May 2020 Uncategorised 0

The approval gives NSCLC patients whose tumours carry the MET exon 14 skipping mutation a new treatment option

More: Speedy US approval for Novartis' Tabrecta
Source: News